Très fier de soutenir Clarissa Desjardins et son équipe à Congruence Thérapeutique afin de faire progresser sa plateforme ciblant les maladies rares. newswire.ca/fr/news-releas…

Great transaction for the Canadian precision oncology ecosystem! Oncology innovators Canexia Health, Imagia merge, raise $20 million betakit.com/oncology-innov… via @betakit

On this International Day of Women and Girls in Science, I really would like to highlight the contribution of Allyson Tighe Juliana M and Nancy Harrison to our ecosystem! Our blogpost below👇

You bet statnews.com/2022/02/14/why…

You want to impact health ? Apply here !👇

Do you want to impact healthcare innovation ? Apply here ! 👇

Flight delayed… sigh… This never happens on Zoom.

Bienvenue à tous les nouveaux membres d’ Espace CDPQ ! Bien hâte de vous rencontrer autour de la machine à café!

Interested in a career in life sciences ? Register here 👇

We're excited to announce that DrugBank has raised $9M in its latest seed funding round, led by Brightspark! We’ve got big plans and we’re excited you’re along for the ride! #healthtech #drugdiscovery #biotech #pharma

Very pleased to announce our latest investment

Congrats to the whole team!

Will a recession save biotech? Interesting read from Bay Bridge Bio baybridgebio.com/blog/recession…

I’d like to thank the Air Canada customer service person at Toronto Pearson who lied to me without blinking about my luggage following me in the plane.

So true !

Good progress from portfolio company $Thryv_Tx: Completion of Initial Phase 1 Clinical Study and Beginning of Proof of Efficacy Study in Long QT Syndrome — Thryv Therapeutics thryvtrx.com/news/initial-p…

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting newswire.ca/news-releases/…

Innovation on RocketFuel! We are joining forces with Evotec SE to turbocharge precision medicine. evotec.com/en/investor-re…

Currently attending the #Jefferies London Healthcare conference. First in person investor conference in 2 years. I’m rusty …

Biotech capital markets busy: 2 IPOs, 7 follow-ons raised $1.4B last week. Most issuers ended the week up, and some significantly. Four of first six weeks of the 2024 have seen $1B+ raised in public offerings, only eight weeks in all of 2023 got to that level.